In short
A groundbreaking clinical trial is currently underway to evaluate the investigational drug ORG-129 in healthy volunteers. This "First in Human" study aims to assess how safe and well-tolerated ORG-129 is when taken orally, while also examining how the drug moves through the body. The research includes both single and multiple dose administration to understand the drug's behavior and effects in the human body. This initial testing in healthy individuals represents a crucial first step in the drug development process, providing valuable information that may guide future studies of ORG-129 in patient populations.
Key points
- ORG-129 is currently being evaluated in its first human study involving healthy volunteers. This clinical trial investigates the safety and tolerability of the drug when given as single and multiple oral doses. The study also examines how ORG-129 moves through the body (pharmacokinetics) and how food might affect its absorption. The research includes several participant groups receiving either the actual drug or a placebo for comparison purposes. By measuring various aspects of how the body processes ORG-129, including how quickly it reaches peak levels in the bloodstream and how long it stays in the body, researchers will gain valuable insights about this investigational drug. This initial testing in healthy people is an essential first step before potentially studying ORG-129 in patients with specific medical conditions.
At a glance
- Study Title
- First in Human Study of ORG-129 in Healthy Volunteers
- Primary Objective
- To assess safety, tolerability, pharmacokinetics and bioavailability of ORG-129
- Study Population
- Healthy male and female volunteers
- Study Design
- Single ascending dose (SAD) and multiple ascending dose (MAD) study with food interaction assessment
- Drug Administration
- ORG-129 oral capsules vs. placebo oral capsules
- Study Duration
- SAD: 8 days; MAD: 12 days
- Primary Outcomes
- Safety and tolerability measured by treatment emergent adverse events
- Secondary Outcomes
- Comprehensive pharmacokinetic parameters (AUC, Cmax, Tmax, CL/F, Vz/F, Kel, t 1/2, Css)
- Clinical Trial ID
- NCT04933565
What is ORG-129?
ORG-129 is an investigational medication currently in early-stage clinical testing. It is being studied as an oral medication in capsule form. As this drug is still in the initial phase of human testing, the specific conditions it may eventually treat are not yet disclosed in the available clinical trial information. The drug is currently being evaluated in healthy volunteers to establish its basic safety profile before moving to testing in patients with specific medical conditions.
Clinical Testing Status
ORG-129 is currently in what's called a "First in Human" clinical trial. This means it's the very first time the drug is being tested in people after completing necessary laboratory and animal studies. The study is specifically designed to test the drug in healthy volunteers (people without medical conditions) to understand how the body processes the drug and to identify any potential safety concerns before testing it in patients with specific diseases.
How ORG-129 is Administered
ORG-129 is being developed as an oral medication in capsule form. This means that if eventually approved, patients would take the medication by mouth. The current study is evaluating different dosing schedules, including single doses and multiple doses over several days.
Study Design Details
The clinical trial for ORG-129 has several components designed to thoroughly evaluate how the drug behaves in the human body:
- Single Ascending Dose (SAD) - Participants receive a single dose of the medication, with different groups receiving progressively higher doses to find the safe dose range. This helps researchers understand how the body handles a single dose of the medication.
- Multiple Ascending Dose (MAD) - Participants receive multiple doses of the medication over several days, again with different groups receiving progressively higher doses. This helps researchers understand how the body handles repeated exposure to the medication.
- Food Interaction Study - This part of the study examines whether taking the medication with food affects how the body absorbs and processes the drug.
- Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation - This detailed analysis measures how the drug moves through the body (pharmacokinetics) and what effects it has (pharmacodynamics).
The study includes both the actual medication (ORG-129) and a placebo (an identical-looking capsule with no active medication). This design helps researchers determine which effects are actually caused by the medication versus effects that might occur due to other factors.
Safety and Side Effects
A primary goal of this early-stage clinical trial is to assess the safety and tolerability of ORG-129. Researchers are carefully monitoring:
- Treatment emergent adverse events - Any health problems that develop after participants take the medication. These are tracked for their number, severity, and type.
For the single dose portion of the study, safety monitoring continues for 8 days after taking the medication. For the multiple dose portion, monitoring continues for 12 days. This extended monitoring helps researchers identify both immediate and delayed side effects.
Since this is a very early stage study, comprehensive information about side effects is not yet available. Establishing this safety profile is actually one of the main purposes of the current trial.
Understanding Pharmacokinetics of ORG-129
A significant portion of this clinical trial focuses on understanding how ORG-129 behaves in the human body, which is called pharmacokinetics. Several important measurements are being taken:
- Area under the curve (AUC) - This measures the total exposure to the drug over time. It helps determine how much of the drug reaches the bloodstream.
- Maximum concentration (Cmax) - This is the highest level of the drug observed in the blood, indicating how intensely the body is exposed to the drug.
- Time to maximum concentration (Tmax) - This shows how quickly the drug is absorbed and reaches its highest level in the bloodstream.
- Oral clearance (CL/F) - This measures how quickly the body removes the drug from the bloodstream.
- Volume of distribution (Vz/F) - This indicates how widely the drug spreads throughout the body's tissues.
- Elimination rate (Kel) - This shows how rapidly the drug is eliminated from the body.
- Half-life (t 1/2) - This is the time it takes for the concentration of the drug in the body to be reduced by half, which helps determine how often a medication needs to be taken.
- Steady state concentration (Css) - This is the stable level of drug in the body after taking multiple doses over time.
These measurements help researchers understand the appropriate dosing schedule for the medication - including how much to give and how often.
Future Research and Development
As ORG-129 is still in the earliest phase of human testing, much more research will be needed before it could potentially become an approved medication. Future studies would likely include:
- Phase 2 studies - Testing in patients with specific medical conditions to determine if the drug is effective
- Phase 3 studies - Larger scale testing to confirm effectiveness and monitor side effects in more diverse populations
- Regulatory review - Evaluation by health authorities like the FDA to determine if the benefits outweigh the risks
The current study will help determine if ORG-129 has appropriate safety characteristics to continue this development process. The study is also analyzing biomarkers, which are measurable indicators that might show how the drug is affecting the body at a molecular or cellular level.